Exagen Inc reports results for the quarter ended December 31 - Earnings Summary

• Exagen Inc XGN.OQ reported a quarterly adjusted loss of 20 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -31 cents. The mean expectation of six analysts for the quarter was for a loss of 26 cents per share. Wall Street expected results to range from -30 cents to -23 cents per share.

• Revenue fell 0.8% to $13.66 million from a year ago; analysts expected $13.85 million.

• Exagen Inc's reported EPS for the quarter was a loss of 20 cents​.

• The company reported a quarterly loss of $3.76 million.

• Exagen Inc shares had fallen by 30.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the healthcare facilities & services peer group is also "buy"

Wall Street's median 12-month price target for Exagen Inc is $7.00

This summary was machine generated from LSEG data March 11 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)